Iczkowski K A, Bostwick D G, Roche P C, Cheville J C
Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.
Mod Pathol. 1998 Aug;11(8):774-9.
We compared the expression of inhibin A, chromogranin, synaptophysin, S-100 protein, cytokeratins AE1/AE3, 7, and 20, and estrogen and progesterone receptors in testicular sex cord-stromal tumors: 11 Sertoli cell tumors, 3 Sertoli cell adenomas (nodules), 26 benign Leydig cell tumors, 7 malignant Leydig cell tumors (defined clinically by metastatic behavior), and a variety of germ cell tumors. Inhibin was the most sensitive marker, expressed in 91% of the Sertoli cell tumors and 100% of the Sertoli cell adenomas and Leydig cell tumors. The non-neoplastic Sertoli and Leydig cells invariably stained for inhibin. Conversely, no germ cell tumors were immunoreactive. One testicular tumor of the adrenogenital syndrome was immunoreactive. Neuroendocrine marker immunoreactivity was variable. Chromogranin was expressed in the non-neoplastic Sertoli and Leydig cells, 82% of the Sertoli cell tumors, 92% of the benign Leydig cell tumors, and 43% of the malignant Leydig cell tumors. Synaptophysin was expressed in the non-neoplastic Sertoli and Leydig cells, 45% of the Sertoll cell tumors, and 70% of the Leydig cell tumors, in approximately similar proportions between the benign and malignant Leydig cell tumors. S-100 protein was expressed in 64% of the Sertoli cell tumors, 8% of the benign Leydig cell tumors, and none of the malignant Leydig cell tumors. Cytokeratins AE1/AE3 were expressed in 64% of the Sertoli cell tumors and 42% of the Leydig cell tumors, with similar proportions in the benign and malignant cases. Estrogen and progesterone receptor expression were identified in 24 and 39% of benign and malignant Leydig cell tumors, respectively. We conclude that inhibin is a characteristic marker for Sertoli and Leydig cells and that it serves to differentiate testicular sex cord-stromal tumors from germ cell tumors.
我们比较了抑制素A、嗜铬粒蛋白、突触素、S-100蛋白、细胞角蛋白AE1/AE3、7和20以及雌激素和孕激素受体在睾丸性索间质肿瘤中的表达情况:11例支持细胞瘤、3例支持细胞腺瘤(结节)、26例良性间质细胞瘤、7例恶性间质细胞瘤(根据转移行为临床定义)以及多种生殖细胞肿瘤。抑制素是最敏感的标志物,在91%的支持细胞瘤、100%的支持细胞腺瘤和间质细胞瘤中表达。非肿瘤性支持细胞和间质细胞始终对抑制素呈阳性染色。相反,没有生殖细胞肿瘤呈免疫反应性。1例肾上腺生殖器综合征的睾丸肿瘤呈免疫反应性。神经内分泌标志物的免疫反应性各不相同。嗜铬粒蛋白在非肿瘤性支持细胞和间质细胞、82%的支持细胞瘤、92%的良性间质细胞瘤以及43%的恶性间质细胞瘤中表达。突触素在非肿瘤性支持细胞和间质细胞、45%的支持细胞瘤以及70%的间质细胞瘤中表达,在良性和恶性间质细胞瘤中的比例大致相似。S-100蛋白在64%的支持细胞瘤、8%的良性间质细胞瘤中表达,而在恶性间质细胞瘤中均未表达。细胞角蛋白AE1/AE3在64%的支持细胞瘤和42%的间质细胞瘤中表达,在良性和恶性病例中的比例相似。雌激素和孕激素受体表达分别在24%的良性和39%的恶性间质细胞瘤中被检测到。我们得出结论,抑制素是支持细胞和间质细胞的特征性标志物,它有助于将睾丸性索间质肿瘤与生殖细胞肿瘤区分开来。